The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Chugai Wins First Round in Patent Infringement Lawsuit for Oxarol Ointment
December 26, 2014
- Otsuka Obtains Rights from ARIAD to Develop, Commercialize Ponatinib in Japan and Other Asian Countries
December 26, 2014
- Taiho Completes NDA Submission for Lonsurf in US
December 26, 2014
- Takeda Files NDA for Glatiramer Licensed from Teva for Relapse Prevention of Multiple Sclerosis
December 26, 2014
- Astellas Expands Scope of Collaboration with Cytokinetics in Skeletal Muscular Disease Field
December 25, 2014
- NDA for Selexipag Filed in US by Actelion: Nippon Shinyaku
December 25, 2014
- Fujifilm Completes Acquisition of Kalon Biotherapeutics
December 24, 2014
- AZ, Quintiles Create New Drug Development Team, Fusing Pharma’s Expertise with CRO’s Knowhow
December 24, 2014
- Ono Licenses Exclusive Worldwide Rights for BTK Inhibitor to Gilead Excluding East and South East Asia
December 22, 2014
- Chugai, Yakult File Xeloda, Elplat for Postoperative Adjuvant Chemotherapy for Gastric Cancer
December 22, 2014
- Poteligeo Now Indicated for Chemotherapy-Naïve CCR4-Positive ATL: Kyowa Kirin
December 19, 2014
- Taiho’s Abraxane Gets Nod for Unresectable Pancreatic Cancer
December 19, 2014
- Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
- MTPC Reorganizing Its US Affiliates to Accelerate Operation Expansion
December 19, 2014
- Fujifilm Holdings Makes J-TEC Its Consolidated Subsidiary
December 19, 2014
- Daiichi Sankyo Looks to Bring Annual 8-10 Projects into Clinical Phase, Open Innovation Key to Success: R&D Execs
December 18, 2014
- CRO Intellim to Collaborate with Indian Firm for CDISC
December 18, 2014
- Novartis Confirms Additional Cases of Employee Involvement in IIT, but Denies Falsification or Manipulation of Data
December 18, 2014
- Ribomic to Extend Joint Research Term by 1 Year with Otsuka for Hematological Disorder, Fibrosis Projects
December 18, 2014
- Chugai to File for Approval of Xeloda as Gastric Cancer Adjuvant Therapy by Year-End
December 17, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…